Profile data is unavailable for this security.
About the company
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
- Revenue in JPY (TTM)0.00
- Net income in JPY-2.32bn
- Incorporated2016
- Employees37.00
- LocationModalis Therapeutics Corp4FY's Bldg., 16-5, Nihonbashi Kabuto-choCHUO-KU 103-0023JapanJPN
- Phone+81 368224584
- Websitehttps://www.modalistx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PhoenixBio Co Ltd | 1.72bn | 26.38m | 1.95bn | 65.00 | 136.21 | 1.08 | 59.33 | 1.14 | 3.55 | 3.55 | 409.59 | 446.27 | 0.5983 | 1.28 | 6.80 | -- | 0.9201 | -4.04 | 1.31 | -5.28 | 69.67 | 65.88 | 1.54 | -6.97 | 3.99 | -- | 0.2871 | -- | -19.24 | 6.91 | -94.65 | -- | -9.96 | -- |
| Modalis Therapeutics Corp | 0.00 | -2.32bn | 2.61bn | 37.00 | -- | 2.40 | -- | -- | -72.46 | -72.46 | 0.00 | 29.59 | 0.00 | -- | -- | 0.00 | -103.95 | -29.19 | -112.89 | -30.02 | -- | -- | -- | -597.35 | 9.75 | -- | 0.2638 | -- | -100.00 | -- | 11.50 | -- | 135.50 | -- |
| D.Western Therapeutics Institute Inc | 443.18m | -1.04bn | 2.94bn | 21.00 | -- | 3.05 | -- | 6.63 | -32.29 | -32.29 | 13.84 | 29.84 | 0.1784 | 0.472 | 3.10 | 21,103,950.00 | -42.16 | -13.06 | -45.11 | -14.36 | 91.32 | 94.29 | -236.36 | -72.51 | 11.65 | -- | 0.509 | -- | -4.40 | 7.90 | -89.07 | -- | 7.08 | -- |
| Muromachi Chemicals Inc | 6.12bn | 216.69m | 2.99bn | 205.00 | 13.66 | 1.38 | 8.51 | 0.4884 | 53.45 | 53.45 | 1,503.34 | 527.87 | 1.20 | 3.83 | 3.75 | 29,862,370.00 | 4.23 | -- | 6.84 | -- | 28.31 | -- | 3.54 | -- | 1.45 | 26.20 | 0.4483 | -- | 10.74 | -- | -43.83 | -- | -- | -- |
| Ribomic Inc | 0.00 | -1.02bn | 3.10bn | 25.00 | -- | 0.9024 | -- | -- | -28.70 | -28.70 | 0.00 | 94.20 | 0.00 | -- | -- | -- | -25.19 | -30.52 | -26.34 | -31.71 | -- | -- | -- | -1,777.84 | 22.49 | -- | -- | -- | -100.00 | -- | 38.04 | -- | 4.42 | -- |
| Atect Corp | 3.18bn | -244.35m | 3.13bn | 96.00 | -- | 1.77 | 9.05 | 0.9849 | -55.27 | -55.27 | 718.38 | 398.84 | 0.5895 | 3.30 | 6.85 | -- | -4.54 | 0.7132 | -6.41 | 0.9718 | 43.40 | 47.04 | -7.69 | 1.32 | 0.6992 | -- | 0.5902 | 84.76 | 7.23 | 1.45 | -253.71 | -- | -23.49 | 0.00 |
| Human Metabolome Technologies Inc | 1.34bn | 285.75m | 3.84bn | 57.00 | 13.43 | 1.99 | 10.38 | 2.87 | 48.31 | 48.31 | 226.62 | 326.17 | 0.5643 | 17.82 | 3.80 | 23,500,000.00 | 12.04 | -- | 15.43 | -- | 63.89 | -- | 21.33 | -- | 3.84 | 124.76 | 0.1061 | -- | 6.21 | -- | 6.71 | -- | -- | -- |
| Kubota Pharmaceutical Holdings Co Ltd | 39.74m | -1.39bn | 3.88bn | 12.00 | -- | 1.66 | -- | 97.74 | -24.82 | -24.82 | 0.711 | 41.58 | 0.0118 | 0.3815 | 26.89 | 3,312,000.00 | -41.32 | -36.51 | -45.53 | -39.47 | 72.88 | -- | -3,492.38 | -13,528.87 | 8.97 | -- | 0.0555 | -- | 383.24 | -- | 26.11 | -- | 24.38 | -- |
Data as of May 29 2024. Currency figures normalised to Modalis Therapeutics Corp's reporting currency: Japanese Yen JPY
8.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nikko Asset Management Co., Ltd.as of 27 Sep 2022 | 1.42m | 3.86% |
| Rheos Capital Works, Inc. (Investment Management)as of 25 Apr 2023 | 1.40m | 3.79% |
| Chibagin Asset Management Co. Ltd.as of 30 May 2022 | 147.30k | 0.40% |
| JPMorgan Asset Management (Japan) Ltd.as of 12 Sep 2022 | 2.90k | 0.01% |
| Manulife Investment Management (Hong Kong) Ltd.as of 30 Jun 2023 | 0.00 | 0.00% |
| SPARX Asset Management Co., Ltd.as of 17 Oct 2022 | 0.00 | 0.00% |
| Daiwa Asset Management Co. Ltd.as of 29 Aug 2022 | 0.00 | 0.00% |
| Asset Management One Co., Ltd.as of 16 Sep 2022 | 0.00 | 0.00% |
| Amundi Japan Ltd.as of 12 Sep 2022 | 0.00 | 0.00% |
| SBI Okasan Asset Management Co. Ltd.as of 22 Mar 2022 | 0.00 | 0.00% |
More ▼
Data from 10 Mar 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
